Picture of Dr. Petros Papagerakis

Dr. Petros Papagerakis Associate Dean, Research & Associate Professor

Dr. Petros Papagerakis graduated from the School of Dentistry-Aristotle University, Thessaloniki, Greece. He completed postgraduate training at the University of Paris (France) in Pediatric and Preventive Dentistry, Hospital Pediatric Dentistry, Biomedical Sciences (BSc), Oral Biology (MSc), and Cellular and Developmental Biology (PhD). He also completed a NIH-funded post-doctoral training in Craniofacial Molecular Genetics at the University of Texas, USA. Petros served as faculty of Dentistry (primary) and Medicine (affiliated) at the 7th University of Paris, the University of Texas and the University of Michigan before his recent relocation at the University of Saskatchewan.

Address
4D01.13 - 107 Wiggins Road, Saskatoon, SK S7N 5E5

Research interests

Dr. Papagerakis’ research interests are in the field of Precision Health applied in oral diseases pathogenesis and treatment, and in the area of dental tissue repair and regeneration using novel dental biomaterials and/or stem cells. Of particular interest is the study of the effects of circadian rhythms disruption and environmental exposure to carcinogenic molecules in relation with saliva biomarker development and the development of targeted personalized treatment for patients with Sjögrens Syndrome (the second most common autoimmune disease) and Oral Cancer (one of the major cancers with very poor survival rate). A second particular interest is in the area of Community and Preventive Health and the development of interventional strategies and the design and implementation of pre-clinical testing and clinical trials of novel biomaterials to prevent and treat dental infectious diseases.

Funding Success

Dr. Petros Papgerakis recieved one of three 2017 International Innovation Award in Dental Research (IADR). This is the most prestigious award and each year they receive 70 or more applications from all over the world. The award comes with a $50,000 grant from GSK to advance innovation to the next stage.